Government announces £340m uplift for community pharmacy alongside rollout of prescribing powers

29 May 2026

3 min read

Health, Regulatory & Professional Conduct

A person in a white lab coat stands in a bright pharmacy aisle, holding a clipboard and checking notes beside shelves of medicines.

The Government has announced a £340m uplift to the Community Pharmacy Contract for 2026/27, alongside confirmation that pharmacist independent prescribing will be rolled out as an NHS-funded service from Autumn 2026.

The reforms form part of a broader shift towards community pharmacy playing a more central clinical role within primary care.

Here, Thorrun Govind and Richard Hough from our specialist pharmacy team break down the changes and outline their impact on the sector.

Expansion of clinical services

Under the new contractual framework, appropriately qualified pharmacist independent prescribers will be able to assess patients and prescribe medicines directly on the NHS, building on existing services such as Pharmacy First.

The intention is to improve access to care through high street pharmacies, reducing pressure on GP services and enabling patients to receive treatment more quickly and conveniently.

Policy direction & sector impact

The announcement reflects a continued move towards delivering more care in community settings, with pharmacies expected to take on an expanded role in managing common conditions and delivering frontline clinical services.

Alongside the funding uplift, the decision to write off historic medicines margin over-delivery removes the risk of repayment of that historic amount and provides a degree of financial certainty as contractors adapt to a more service-led model.

Legal & regulatory considerations

From a legal and regulatory perspective, the rollout of prescribing responsibilities raises important considerations for pharmacy owners and teams. As new clinical services are embedded into contractual frameworks, organisations will need to ensure that robust governance arrangements are in place, including clearly defined lines of professional accountability, appropriate indemnity cover and effective workforce training.

Operational considerations will also remain critical, particularly in relation to capacity, delegation, supervision, record-keeping and patient safety as prescribing responsibilities are introduced at scale across the sector.

Hear from our experts

Present at the announcement, Solicitor, pharmacist and former Chair of the Royal College of Pharmacy, Thorrun Govind, said: “Community pharmacy is increasingly being recognised as a vital access point for patient care. While the rollout of independent prescribing as an NHS service is a significant step forward, it also brings a heightened need for clear governance, strong clinical frameworks and careful implementation to ensure that patient safety remains at the centre of service delivery.”

Richard Hough, Head of Healthcare, added: “We work closely with pharmacy owners and operators across the country and understand the real pressures that they’re facing on the ground. While this announcement represents a positive step, our clients will be focused on whether these reforms are deliverable in practice, particularly in the context of workforce constraints and ongoing financial challenges.”

Looking ahead

While the funding uplift represents a further step forward, sector bodies have indicated that it remains below the level identified in NHS England’s independent economic analysis as necessary to secure the long-term financial sustainability of community pharmacy. As a result, the success of the reforms is likely to depend not only on their policy ambition but on whether they can be delivered in a way that’s both operationally sustainable and legally robust for providers across the sector.

Talk to us

Drawing on deep experience across the healthcare sector, we advise organisations and practising professionals on regulatory, commercial and strategic matters, supporting pharmacists, dentists, doctors and paramedics.

If you’d like to discuss how these developments may impact your pharmacy business or organisation, give us a call on 0333 004 4488, email hello@brabners.com or fill in our contact form.